Biopharma investment strategies shift due to IRA – On the last day of BIO’s 2023 Investor Forum, the discussion focused on the Inflation Reduction Act and its impact on biopharma investment decisions, which will now require companies to reevaluate their existing strategies to cover potential scenarios because of the IRA in the next 18 to 20 months. John Murphy, BIO’s Chief Policy Officer, cited the
potential of the Optimizing Research Progress Hope and New Cures or ORPHAN Cures Act as a possible buffer to the IRA’s impact, aside from the fact that there is a push “to make some changes that could be beneficial in the short term. I do think we are going to see this law-should it stand-undergo some
changes,” Murphy said.

Click here to download the document.

About the author.


20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

No Comments. Leave a comment  

Leave a Reply

Your email address will not be published. Required fields are marked *